SCHEMBL9944360

SCHEMBL9944360

CCCCOc1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc(Cl)c1OCCCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
PLAU P00749 1/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
TAS1R2 Q8TE23 1/20 0.51
NR1H4 Q96RI1 3/20 0.51
LMNA P02545 3/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
MCL1 Q07820 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
PDE4A P27815 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1457725 0.87 PLAU (0.62) MAPTNPSR1PLAUMEN1KMT2A
SCHEMBL9944295 0.87 MAPT (0.54) MAPTNPSR1PLAUMEN1KMT2A
SCHEMBL1458097 0.83 MEN1 (0.63) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL1458773 0.82 MEN1 (0.75) MAPTPLAUMEN1KMT2ANPC1
SCHEMBL17525297 0.81 MEN1 (0.58) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL1458304 0.81 MEN1 (0.58) MAPTNPSR1PLAUMEN1KMT2A
SCHEMBL1458087 0.81 MEN1 (0.60) MAPTNPSR1PLAUMEN1KMT2A
SCHEMBL1458529 0.80 MEN1 (0.56) MAPTNPSR1MEN1KMT2ANPC1
SCHEMBL1458289 0.80 MRGPRX4 (0.56) PLAUMEN1KMT2ANPC1RAB9A
SCHEMBL1457750 0.78 GAA (0.71) MAPTMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885NPSR1 826/4885PLAU 4014/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885NPSR1 826/4885PLAU 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.